QQQ   355.09 (+0.05%)
AAPL   179.46 (-0.07%)
MSFT   334.18 (-0.52%)
META   272.18 (+0.29%)
GOOGL   128.09 (+1.65%)
AMZN   126.79 (+1.19%)
TSLA   220.39 (+1.28%)
NVDA   387.78 (-1.00%)
NIO   7.85 (+2.35%)
BABA   86.99 (+3.07%)
AMD   123.87 (+5.04%)
T   15.63 (+1.56%)
F   12.91 (+2.54%)
MU   67.57 (-0.30%)
CGC   0.74 (-5.76%)
GE   105.43 (+1.28%)
DIS   92.27 (+1.40%)
AMC   4.62 (-0.22%)
PFE   38.34 (-0.80%)
PYPL   65.02 (+0.79%)
NFLX   399.41 (-1.02%)
QQQ   355.09 (+0.05%)
AAPL   179.46 (-0.07%)
MSFT   334.18 (-0.52%)
META   272.18 (+0.29%)
GOOGL   128.09 (+1.65%)
AMZN   126.79 (+1.19%)
TSLA   220.39 (+1.28%)
NVDA   387.78 (-1.00%)
NIO   7.85 (+2.35%)
BABA   86.99 (+3.07%)
AMD   123.87 (+5.04%)
T   15.63 (+1.56%)
F   12.91 (+2.54%)
MU   67.57 (-0.30%)
CGC   0.74 (-5.76%)
GE   105.43 (+1.28%)
DIS   92.27 (+1.40%)
AMC   4.62 (-0.22%)
PFE   38.34 (-0.80%)
PYPL   65.02 (+0.79%)
NFLX   399.41 (-1.02%)
QQQ   355.09 (+0.05%)
AAPL   179.46 (-0.07%)
MSFT   334.18 (-0.52%)
META   272.18 (+0.29%)
GOOGL   128.09 (+1.65%)
AMZN   126.79 (+1.19%)
TSLA   220.39 (+1.28%)
NVDA   387.78 (-1.00%)
NIO   7.85 (+2.35%)
BABA   86.99 (+3.07%)
AMD   123.87 (+5.04%)
T   15.63 (+1.56%)
F   12.91 (+2.54%)
MU   67.57 (-0.30%)
CGC   0.74 (-5.76%)
GE   105.43 (+1.28%)
DIS   92.27 (+1.40%)
AMC   4.62 (-0.22%)
PFE   38.34 (-0.80%)
PYPL   65.02 (+0.79%)
NFLX   399.41 (-1.02%)
QQQ   355.09 (+0.05%)
AAPL   179.46 (-0.07%)
MSFT   334.18 (-0.52%)
META   272.18 (+0.29%)
GOOGL   128.09 (+1.65%)
AMZN   126.79 (+1.19%)
TSLA   220.39 (+1.28%)
NVDA   387.78 (-1.00%)
NIO   7.85 (+2.35%)
BABA   86.99 (+3.07%)
AMD   123.87 (+5.04%)
T   15.63 (+1.56%)
F   12.91 (+2.54%)
MU   67.57 (-0.30%)
CGC   0.74 (-5.76%)
GE   105.43 (+1.28%)
DIS   92.27 (+1.40%)
AMC   4.62 (-0.22%)
PFE   38.34 (-0.80%)
PYPL   65.02 (+0.79%)
NFLX   399.41 (-1.02%)
NASDAQ:AMGN

Amgen (AMGN) Competitors

$220.77
-1.11 (-0.50%)
(As of 03:11 PM ET)
Compare
Today's Range
$219.28
$223.17
50-Day Range
$214.27
$253.37
52-Week Range
$211.71
$296.67
Volume
1.05 million shs
Average Volume
2.39 million shs
Market Capitalization
$117.96 billion
P/E Ratio
15.01
Dividend Yield
3.86%
Price Target
$250.94

AMGN vs. GILD, BIIB, SGEN, MRNA, MDT, ISRG, SNY, ELV, SYK, and BMY

Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Biogen (BIIB), Seagen (SGEN), Moderna (MRNA), Medtronic (MDT), Intuitive Surgical (ISRG), Sanofi (SNY), Elevance Health (ELV), Stryker (SYK), and Bristol-Myers Squibb (BMY). These companies are all part of the "medical" sector.

Amgen vs.

Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.

Amgen pays an annual dividend of $8.52 per share and has a dividend yield of 3.9%. Gilead Sciences pays an annual dividend of $3.00 per share and has a dividend yield of 3.9%. Amgen pays out 57.9% of its earnings in the form of a dividend. Gilead Sciences pays out 67.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

75.5% of Amgen shares are held by institutional investors. Comparatively, 78.7% of Gilead Sciences shares are held by institutional investors. 0.6% of Amgen shares are held by insiders. Comparatively, 0.2% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amgen has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.

Gilead Sciences received 949 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 77.92% of users gave Gilead Sciences an outperform vote while only 72.99% of users gave Amgen an outperform vote.

CompanyUnderperformOutperform
AmgenOutperform Votes
1486
72.99%
Underperform Votes
550
27.01%
Gilead SciencesOutperform Votes
2435
77.92%
Underperform Votes
690
22.08%

Amgen currently has a consensus price target of $250.94, suggesting a potential upside of 13.89%. Gilead Sciences has a consensus price target of $91.00, suggesting a potential upside of 19.25%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
4 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.15
Gilead Sciences
0 Sell rating(s)
8 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.53

Amgen has a net margin of 30.23% compared to Gilead Sciences' net margin of 20.65%. Amgen's return on equity of 248.47% beat Gilead Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen 30.23% 248.47% 13.54%
Gilead Sciences 20.65% 39.35% 13.11%

In the previous week, Gilead Sciences had 4 more articles in the media than Amgen. MarketBeat recorded 24 mentions for Gilead Sciences and 20 mentions for Amgen. Gilead Sciences' average media sentiment score of 0.46 beat Amgen's score of 0.04 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
2 Very Positive mention(s)
7 Positive mention(s)
3 Neutral mention(s)
6 Negative mention(s)
2 Very Negative mention(s)
Neutral
Gilead Sciences
8 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

Amgen has higher earnings, but lower revenue than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$26.32 billion4.48$6.55 billion$14.7115.01
Gilead Sciences$27.28 billion3.48$4.59 billion$4.4317.17

Summary

Gilead Sciences beats Amgen on 11 of the 20 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMGN vs. The Competition

MetricAmgenBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$117.96B$2.67B$4.52B$6.29B
Dividend Yield3.91%2.33%5.98%6.51%
P/E Ratio15.013.3485.5112.01
Price / Sales4.48197.763,500.5496.14
Price / Cash8.9616.6622.3423.57
Price / Book32.183.694.715.38
Net Income$6.55B$57.90M$116.80M$192.53M
7 Day Performance1.03%12.63%4.47%3.49%
1 Month Performance-6.66%13.29%2.28%4.88%
1 Year Performance-10.05%21.15%15.56%2.78%

Amgen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GILD
Gilead Sciences
3.2031 of 5 stars
$76.33
-1.0%
$91.00
+19.2%
+22.5%$95.21B$27.28B17.2317,000
BIIB
Biogen
2.1976 of 5 stars
$298.69
+0.0%
$328.38
+9.9%
+50.6%$43.23B$10.17B13.878,725
SGEN
Seagen
1.9944 of 5 stars
$194.01
+0.3%
$190.47
-1.8%
+39.5%$36.38B$1.96B-55.593,256Analyst Report
MRNA
Moderna
2.2007 of 5 stars
$128.89
+2.1%
$179.13
+39.0%
-6.0%$49.13B$14.77B11.143,900
MDT
Medtronic
2.8582 of 5 stars
$82.51
+1.3%
$91.37
+10.7%
-12.3%$109.77B$31.23B29.2695,000
ISRG
Intuitive Surgical
2.5654 of 5 stars
$307.07
+0.1%
$300.50
-2.1%
+45.8%$107.60B$6.22B83.9012,120Analyst Report
SNY
Sanofi
2.466 of 5 stars
$50.45
-3.9%
$94.50
+87.3%
-5.0%$127.23B$45.31B18.0891,573Dividend Cut
ELV
Elevance Health
3.2883 of 5 stars
$441.60
-1.0%
$570.60
+29.2%
-2.6%$104.69B$156.60B17.18102,300
SYK
Stryker
3.258 of 5 stars
$271.49
-0.4%
$302.00
+11.2%
+21.4%$102.85B$18.45B39.5251,000Insider Selling
BMY
Bristol-Myers Squibb
2.4718 of 5 stars
$63.70
-0.2%
$79.43
+24.7%
-12.2%$133.82B$46.16B18.5734,300Analyst Revision

Related Companies and Tools

This page (NASDAQ:AMGN) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -